Axcelis Technologies
Builds ion implanters and lifecycle services for silicon and silicon-carbide chip production.
Something off on this page? Send us feedback.
Profile
Sells Purion and Ovation ion implanters to semiconductor fabs and earns aftermarket revenue from parts, upgrades, used tools, maintenance, and training. Power-device applications account for most recent annual system shipments by value, while sales depend on chipmakers' capital spending and U.S. export controls affecting China.
Builds and services ion-implantation equipment used to place dopants into silicon and silicon-carbide wafers during chip fabrication. The Purion family spans high-current, high-energy, and medium-current systems; its Power Series targets power-device production, while Ovation serves batch implantation. Customer Solutions & Innovation supplies used tools, parts, upgrades, maintenance, and training across the installed base.
Pairs a common-platform product architecture with in-house system assembly and testing, while sourcing non-core modules from global partners. Power-device applications represented most of the latest annual system shipment value. Most sales are international, and China has been a significant market, tying shipments to U.S. export controls. An all-stock merger with Veeco remains pending final regulatory approval in China.
Company facts
Key statistics
Year to date +34.0% · Average volume (30d) 370.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Craig-Hallum | Downgrade | Buy | Hold | $174 | $140 |
| Apr 20, 2026 | B. Riley Securities | Upgrade | Neutral | Buy | ||
| Oct 13, 2025 | B of A Securities | Downgrade | Neutral | Underperform | ||
| Oct 2, 2025 | DA Davidson | Reiterate | Buy | $75 | $110 | |
| Oct 2, 2025 | Benchmark | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.89 | $1.06 | +18.6% | $205.0M | $215.2M | +4.9% | −0.01% |
| May 7, 2026Q1 FY26 | $0.71 | $0.72 | +1.4% | $195.0M | $199.0M | +2.0% | +2.75% |
| Feb 17, 2026Q4 FY25 | $1.12 | $1.49 | +33.0% | $215.0M | $238.3M | +10.8% | −16.74% |
| Nov 4, 2025Q3 FY25 | $1.01 | $1.21 | +19.8% | $215.0M | $213.6M | −0.7% | +4.89% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $192.6M | $194.5M | $213.6M | $238.3M | $199.0M | $215.2M | |
| Gross profit | $88.8M | $87.3M | $88.8M | $111.9M | $80.6M | $91.2M | |
| Operating income | $29.2M | $29.0M | $25.0M | $36.2M | $8.0M | $20.3M | |
| Net income | $28.6M | $31.4M | $26.0M | $34.3M | $9.2M | $23.3M | |
| Diluted EPS | $0.88 | $0.98 | $0.83 | $1.10 | $0.30 | $0.75 | |
| Gross margin | 46.1% | 44.9% | 41.6% | 47.0% | 40.5% | 42.4% | |
| Operating margin | 15.1% | 14.9% | 11.7% | 15.2% | 4.0% | 9.4% |
Fiscal years (4-quarter sums)FY21 $662.4M · FY22 $920.0M · FY23 $1.13B · FY24 $1.02B · FY25 $839.0M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $402.2M · Total debt $41.6M · Total assets $1.39B · Shareholders' equity $1.07B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 30.73M · Float 30.53M · 99.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.03M | 16.36% | 13F | Aug 7, 2026 |
| FMR LLC | 4.13M | 13.42% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 2.48M | 8.07% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.39M | 4.51% | 13F | Aug 13, 2026 |
| State Street Corp | 1.23M | 4.01% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 3, 2026 | Necip Sayiner | director | −1,586 | $157.44 |
| May 27, 2026 | Todd Sutton | officer: VP Corporate Controller | −2,000 | $159.99 |
| May 22, 2026 | Thomas st Dennis | director | −900 | $155.37 |
| May 21, 2026 | Gerald M. Blumenstock | officer: EVP, Research, Dev. & Eng. | −1,161 | $152.70 |
| May 22, 2026 | Eileen Evans | officer: EVP, General Counsel and Sec'y | −926 | $155.51 |
Peers
- Applied Materials
Only other full-range ion implant vendor; Varian-heritage platform, ~60% share.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Axcelis Technologies | $115.63 | +0.17% | $3.55B | 38.8 | 23.9 | 4.1 | +10.6% |
| Applied Materials | $462.35 | +0.16% | $366.55B | 39.8 | 26.2 | 11.9 | +24.8% |
| Median | 39.8 | 26.2 | 11.9 | +24.8% |